Covid-19 Vaccines in Development and Use
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a positive sense, single-stranded RNA beta coronavirus, a member of Beta-CoV lineage B (subgenus Sarbecovirus).
Here is a list of approved vaccines and vaccines in development. This data is for informational purposes only, not medical advice.
Table 1. Vaccines In Use
Candidate | Status/clinical trials | Sponsor/Producer | Number of countries vaccine being used | Efficacy, % |
---|---|---|---|---|
Vaxzevria (CoviShield) AZD1222 (ChAdOx1) Viral vector |
Phase III NCT04516746 NCT04540393 Phase I/II NCT04568031 NCT04686773 |
AstraZeneca, University of Oxford | 184 | 63.0 https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know |
Comirnaty BNT162b2 mRNA vaccine |
Phase III NCT04713553(completed) NCT04848584 |
BioNTech in collaboration with Pfizer | 124 | 95.0 https://www.who.int/ru/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine |
Spikevax mRNA-1273 mRNA vaccine |
Phase IIINCT04860297Phase IINCT04847050Phase I NCT04283461 NCT04785144 |
NIAID in collaboration with ModernaTherapeutics | 71 | 94.1 https://www.who.int/publications/i/item/interim-recommendations-for-use-of-the-moderna-mrna-1273-vaccine-against-covid-19 |
BBIBP-CorV Inactivated virus |
Phase I/II NCT04993560 |
Sinopharm-Beijing | 68 | 86.0 https://gulfnews.com/uae/health/uae-ministry-of-health-announces-86-per-cent-vaccine-efficacy-1.1607490555571 |
JNJ-78436735 (Ad26.COV2.S)Viral vector | Phase III NCT04505722 |
Johnson & Johnson | 48 | 66.9 https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-what-you-need-to-know |
Sputnik V Gam-COVID-Vac, Gam-COVID-VacLyo Viral vector |
Phase I/II clinical trial in Russia NCT04436471 NCT04437875 Phase III NCT04530396 |
Gamaleya Research Institute | 46 | 94.0 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext |
CoronaVac Inactivated virus |
Phase III clinical trial in BrazilNCT04456595 Phase IV NCT04789356 |
Sinovac, ButantanInstitute | 41 | 51 |
Covaxin BBV-152 Inactivated virus |
Phase I/II NCT04471519 Phase III NCT04641481 |
Bharat Biotech | 7 | - |
Recombinant Coronavirus vaccine | Phase II NCT04313127 NCT04341389 |
CanSinoBiologics Inc. | 5 | - |
Table 2. Vaccines in development
Candidate | Vaccine type | Status/clinical trials | Sponsor/Producer |
---|---|---|---|
AdimrSC-2f | protein subunit | Phase I Clinical Trials in TaiwanNCT04522089 | Adimmune Corporation |
siRNA | RNA | Preclinical development | Alnylam and Vir Biotechnology |
ZF2001 | protein subunit | Phase III | AnhuiZhifei Longcom |
ARCT-021 | RNA | Phase II NCT04728347 | Arcturus Therapeutics |
BBV-154 | viral vector | Phase I NCT04751682 | Bharat Biotech |
SCB-2019 | protein subunit | Phase I NCT04932824 | Clover Biopharmaceuticals |
COVI-VAC | live-attenuated | Phase I NCT04619628 | Codagenix |
UB-612 | multitope peptide-based vaccine (MPV) | Phase I NCT04545749 | COVAXX, United Biomedical |
CVnCoV | mRNA | Phase III NCT04860258 | Curevac |
Vaccine adjuvant CpG1018 | Phase III NCT05012787 | Dynavax Technologies Corp | |
Coronavirus vaccine | Preclinical development | Geovax | |
Vaccine adjuvant | Preclinical development (adjuvant to S-Trimer vaccine) |
GlaxoSmithKline | |
Self-assembling vaccine (SAV) | Preclinical development | HaloVax (Hoth Therapeutics + Voltron Therapeutics) | |
Coronavirus vaccine | Preclinical development | Heat Biologics Inc. | |
INO-4800 DNA-based vaccine |
DNA | Phase I/II Clinical Trials NCT04447781 NCT04336410 |
Inovio Pharmaceuticals |
ReCoV | protein subunit | Phase I | Jiangsu Rec-Biotechnology Co Ltd |
MVC-COV1901 | protein subunit | Phase I/II NCT04487210 NCT04951388 | Medigen |
mRNA-1283 | mRNA | Phase I NCT04813796 | NIAID in collaboration with Moderna Therapeutics |
NVX-CoV2373 Coronavirus vaccine |
protein subunit | Preclinical development | Novavax Inc |
CoVepiT (OSE13E) | protein subunit | Phase I NCT04885361 | OSE Immunotherapeutics |
TAK-019 (Novavax formulation) | protein subunit | Phase I/II NCT04712110 | Takeda |
adjuvanted recombinant protein vaccine | Phase II/III NCT04762680 | Sanofi Pasteur with GSK |
Topics: Novel Therapeutics
Comments:
There are no comments yet. You can be the first.
Leave a Reply cancel reply
Your email address will not be published. Required fields are marked *